Epidermal growth factor receptor (EGFR, ErbB1, Her-1) is a cell surface molecule
overexpressing in a variety of human malignancies and, thus, is an excellent target for …

The invention is directed to modified T cells, methods of making and using isolated, modified
T cells, and methods of using these isolated, modified T cells to address diseases and …

The successful treatment of hematological malignancies remains challenging. Prognosis is
often dismal given the frequency of disease relapse or treatment refractory disease …

A key feature of the clinical course of chronic lymphocytic leukemia (CLL) is that it induces a
state of immunosuppression, causing increased susceptibility to infections and failure of anti …

Adoptive transfer of T cells genetically modified by TCRs or CARs represents a highly
attractive novel therapeutic strategy to treat malignant diseases. Various approaches for the …

World population has experienced continuous growth since 1400 AD Current projections
show a continued increase-but a steady decline in the population growth rate-with the …

Radiation of tumor cells can lead to the selection and outgrowth of tumor escape variants. As
radioresistant tumor cells are still sensitive to retargeting of T cells, it appears promising to …

Melanoma has traditionally been considered an immunogenic tumor. A number of
approaches have been studied for enhancement of antitumor immunity. The first cytokine …

Progress in the use of traditional chemotherapy and radiation‐based strategies for the
treatment of pediatric malignancies has plateaued in the past decade, particularly for …

The invention is directed to modified T cells, methods of making and using isolated, modified
T cells, and methods of using these isolated, modified T cells to address diseases and …